TheraVet Extends the Use of BIOCERA-VET to a New Curative Approach of Osteosarcoma in Dogs Through an Innovative & Multidisci...
02 Juillet 2021 - 07:30AM
Business Wire
Regulatory News:
TheraVet (ISIN: BE0974387194 - ticker: ALVET), a biotechnology
company specialising in osteoarticular treatments for animals,
today announces a new use of BIOCERA-VET in a multidisciplinary
approach to the treatment of osteosarcoma in dogs.
In addition to its ongoing clinical trial in appendicular
osteosarcoma as a palliative alternative to limb amputation in
dogs, TheraVet is currently evaluating the use of BIOCERA-VET as
part of a comprehensive, multidisciplinary and curative approach to
the treatment of osteosarcoma in dogs. This innovative treatment
consists of a combination of tumour removal, reinforcement of the
affected bone by cementoplasty and treatment of the cancer by
immunochemical therapy, thus avoiding amputation.
In this context, TheraVet participated in the treatment of
Flash, a 10 year old Rottweiler cross with a stage 1 osteosarcoma
of the distal radius1, by a multidisciplinary team from the
Occitanie veterinary clinic and the National Veterinary School of
Toulouse, supervised by Dr. Vet David Sayag, European specialist in
pet oncology (ONCOnseil -Unité d'expertise en oncologie, Toulouse,
France). In order to preserve his quality of life and avoid
amputation, Flash's bone tumour was destroyed by image-guided
microwave ablation followed by consolidation of the affected bone
by cementoplasty using the BIOCERA-VET product according to a
procedure developed by Olivier Gauthier, Professor of Small Animal
Surgery and Veterinary Dentistry at the National Veterinary School
Oniris (Nantes, France). Thanks to the care of the veterinarians
and the properties of BIOCERA-VET, Flash was walking normally the
day after his operation and had an excellent quality of life two
weeks after the operation.
The patient is now undergoing immuno-chemotherapy with no side
effects. One month after the surgical treatment and the
implementation of adjuvant treatments, Flash's quality of life has
been maintained and he has resumed normal activity.
The management of animals with osteosarcoma through a
comprehensive approach such as the one proposed by Dr Sayag is a
very high potential alternative to amputation. TheraVet is proud of
the use of BIOCERA-VET in this innovative treatment which marks a
new milestone in veterinary oncology.
"When planning microwave ablation of a bone tumour, the risk of
pathological fracture is greatly increased. In order to minimise
this risk, image-guided sequential cementoplasty is a standard in
interventional radiology. Bone healing with the BIOCERA-VET has
been an asset in the consolidation and improvement of Flash's
quality of life, and we now hope to strengthen our multimodal
management of osteosarcoma with this new approach," comments Dr
David Sayag.
About TheraVet SA
TheraVet is a veterinary biotechnology company specialising in
osteoarticular treatments for animals. The Company develops
targeted, safe and effective treatments to improve the quality of
life of pets suffering from osteoarticular diseases. For pet
owners, the health of their pets is a major concern and TheraVet’s
mission is to address the need for innovative and curative
treatments. TheraVet works closely with international opinion
leaders in order to provide a more effective response to
ever-growing needs in the field of veterinary medicine. TheraVet is
listed on Euronext Growth® Paris et Brussels, its head office is in
Jumet, Belgium, and it has a subsidiary in the US.
For more information, visit www.thera.vet
1 According to the WHO classification
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210701005842/en/
TheraVet Sabrina Ena Chief Operating Officer
sabrina.ena@thera.vet Tel: +32 (0) 71 18 32 49
Julie Winand Chief Corporate Officer julie.winand@thera.vet Tel:
+32 (0) 71 18 32 49
NewCap Investor Relations and Financial Communications
Louis Tilquin / Olivier Bricaud theravet@newcap.eu Tel: +33 (0)1 44
71 94 94
Press Relations Arthur Rouillé / Ambre Delval theravet@newcap.eu
Tel: +33 (0)1 44 71 00 15
TheraVet (EU:ALVET)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
TheraVet (EU:ALVET)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024